



## 103RD GENERAL ASSEMBLY

### State of Illinois

2023 and 2024

**HB4352**

Introduced 1/16/2024, by Rep. Tom Weber

#### SYNOPSIS AS INTRODUCED:

720 ILCS 570/204  
720 ILCS 570/206

from Ch. 56 1/2, par. 1204  
from Ch. 56 1/2, par. 1206

Amends the Illinois Controlled Substances Act. Provides that Xylazine and Clonazolam are to be regulated under the Act as Schedule II controlled substances.

LRB103 35349 RLC 65413 b

1 AN ACT concerning criminal law.

2 **Be it enacted by the People of the State of Illinois,**  
3 **represented in the General Assembly:**

4 Section 5. The Illinois Controlled Substances Act is  
5 amended by changing Sections 204 and 206 as follows:

6 (720 ILCS 570/204) (from Ch. 56 1/2, par. 1204)

7 (Text of Section before amendment by P.A. 103-245)

8 Sec. 204. (a) The controlled substances listed in this  
9 Section are included in Schedule I.

10 (b) Unless specifically excepted or unless listed in  
11 another schedule, any of the following opiates, including  
12 their isomers, esters, ethers, salts, and salts of isomers,  
13 esters, and ethers, whenever the existence of such isomers,  
14 esters, ethers and salts is possible within the specific  
15 chemical designation:

16 (1) Acetylmethadol;

17 (1.1) Acetyl-alpha-methylfentanyl

18 (N-[1-(1-methyl-2-phenethyl)-

19 4-piperidinyl]-N-phenylacetamide);

20 (2) Allylprodine;

21 (3) Alphacetylmethadol, except

22 levo-alphacetylmethadol (also known as levo-alpha-

23 acetylmethadol, levomethadyl acetate, or LAAM);

- 1 (4) Alphameprodine;
- 2 (5) Alphamethadol;
- 3 (6) Alpha-methylfentanyl
- 4 (N-(1-alpha-methyl-beta-phenyl) ethyl-4-piperidyl)
- 5 propionanilide; 1-(1-methyl-2-phenylethyl)-4-(N-
- 6 propanilido) piperidine;
- 7 (6.1) Alpha-methylthiofentanyl
- 8 (N-[1-methyl-2-(2-thienyl)ethyl-
- 9 4-piperidinyl]-N-phenylpropanamide);
- 10 (7) 1-methyl-4-phenyl-4-propionoxypiperidine (MPPP);
- 11 (7.1) PEPAP
- 12 (1-(2-phenethyl)-4-phenyl-4-acetoxypiperidine);
- 13 (8) Benzethidine;
- 14 (9) Betacetylmethadol;
- 15 (9.1) Beta-hydroxyfentanyl
- 16 (N-[1-(2-hydroxy-2-phenethyl)-
- 17 4-piperidinyl]-N-phenylpropanamide);
- 18 (10) Betameprodine;
- 19 (11) Betamethadol;
- 20 (12) Betaprodine;
- 21 (13) Clonitazene;
- 22 (14) Dextromoramide;
- 23 (15) Diampromide;
- 24 (16) Diethylthiambutene;
- 25 (17) Difenoazin;
- 26 (18) Dimenoxadol;

- 1 (19) Dimepheptanol;
- 2 (20) Dimethylthiambutene;
- 3 (21) Dioxaphetylbutyrate;
- 4 (22) Dipipanone;
- 5 (23) Ethylmethylthiambutene;
- 6 (24) Etonitazene;
- 7 (25) Etosexeridine;
- 8 (26) Furethidine;
- 9 (27) Hydroxypethidine;
- 10 (28) Ketobemidone;
- 11 (29) Levomoramide;
- 12 (30) Levophenacylmorphane;
- 13 (31) 3-Methylfentanyl
- 14 (N-[3-methyl-1-(2-phenylethyl)-
- 15 4-piperidyl]-N-phenylpropanamide);
- 16 (31.1) 3-Methylthiofentanyl
- 17 (N-[(3-methyl-1-(2-thienyl)ethyl-
- 18 4-piperidinyl]-N-phenylpropanamide);
- 19 (32) Morpheridine;
- 20 (33) Noracymethadol;
- 21 (34) Norlevorphanol;
- 22 (35) Normethadone;
- 23 (36) Norpipanone;
- 24 (36.1) Para-fluorofentanyl
- 25 (N-(4-fluorophenyl)-N-[1-(2-phenethyl)-
- 26 4-piperidinyl]propanamide);

- 1 (37) Phenadoxone;
- 2 (38) Phenampromide;
- 3 (39) Phenomorphan;
- 4 (40) Phenoperidine;
- 5 (41) Piritramide;
- 6 (42) Proheptazine;
- 7 (43) Properidine;
- 8 (44) Propiram;
- 9 (45) Racemoramide;
- 10 (45.1) Thiofentanyl  
11 (N-phenyl-N-[1-(2-thienyl)ethyl-  
12 4-piperidinyl]-propanamide);
- 13 (46) Tilidine;
- 14 (47) Trimeperidine;
- 15 (48) Beta-hydroxy-3-methylfentanyl (other name:  
16 N-[1-(2-hydroxy-2-phenethyl)-3-methyl-4-piperidinyl]-  
17 N-phenylpropanamide);
- 18 (49) Furanyl fentanyl (FU-F);
- 19 (50) Butyryl fentanyl;
- 20 (51) Valeryl fentanyl;
- 21 (52) Acetyl fentanyl;
- 22 (53) Beta-hydroxy-thiofentanyl;
- 23 (54) 3,4-dichloro-N-[2-  
24 (dimethylamino)cyclohexyl]-N-  
25 methylbenzamide (U-47700);
- 26 (55) 4-chloro-N-[1-[2-

1 (4-nitrophenyl)ethyl]-2-piperidinyldene]-  
2 benzenesulfonamide (W-18);  
3 (56) 4-chloro-N-[1-(2-phenylethyl)  
4 -2-piperidinyldene]-benzenesulfonamide (W-15);  
5 (57) acrylfentanyl (acryloylfentanyl).

6 (c) Unless specifically excepted or unless listed in  
7 another schedule, any of the following opium derivatives, its  
8 salts, isomers and salts of isomers, whenever the existence of  
9 such salts, isomers and salts of isomers is possible within  
10 the specific chemical designation:

- 11 (1) Acetorphine;
- 12 (2) Acetyldihydrocodeine;
- 13 (3) Benzylmorphine;
- 14 (4) Codeine methylbromide;
- 15 (5) Codeine-N-Oxide;
- 16 (6) Cyprenorphine;
- 17 (7) Desomorphine;
- 18 (8) Diacetyldihydromorphine (Dihydroheroin);
- 19 (9) Dihydromorphine;
- 20 (10) Drotebanol;
- 21 (11) Etorphine (except hydrochloride salt);
- 22 (12) Heroin;
- 23 (13) Hydromorphinol;
- 24 (14) Methyldesorphine;
- 25 (15) Methyldihydromorphine;
- 26 (16) Morphine methylbromide;

- 1 (17) Morphine methylsulfonate;
- 2 (18) Morphine-N-Oxide;
- 3 (19) Myrophine;
- 4 (20) Nicocodeine;
- 5 (21) Nicomorphine;
- 6 (22) Normorphine;
- 7 (23) Pholcodine;
- 8 (24) Thebacon.

9 (d) Unless specifically excepted or unless listed in  
10 another schedule, any material, compound, mixture, or  
11 preparation which contains any quantity of the following  
12 hallucinogenic substances, or which contains any of its salts,  
13 isomers and salts of isomers, whenever the existence of such  
14 salts, isomers, and salts of isomers is possible within the  
15 specific chemical designation (for the purposes of this  
16 paragraph only, the term "isomer" includes the optical,  
17 position and geometric isomers):

- 18 (1) 3,4-methylenedioxyamphetamine  
19 (alpha-methyl,3,4-methylenedioxyphenethylamine,  
20 methylenedioxyamphetamine, MDA);  
21 (1.1) Alpha-ethyltryptamine  
22 (some trade or other names: etryptamine;  
23 MONASE; alpha-ethyl-1H-indole-3-ethanamine;  
24 3-(2-aminobutyl)indole; a-ET; and AET);  
25 (2) 3,4-methylenedioxymethamphetamine (MDMA);  
26 (2.1) 3,4-methylenedioxy-N-ethylamphetamine

1 (also known as: N-ethyl-alpha-methyl-  
2 3,4(methylenedioxy) Phenethylamine, N-ethyl MDA, MDE,  
3 and MDEA);

4 (2.2) N-Benzylpiperazine (BZP);

5 (2.2-1) Trifluoromethylphenylpiperazine (TFMPP);

6 (3) 3-methoxy-4,5-methylenedioxyamphetamine, (MMDA);

7 (4) 3,4,5-trimethoxyamphetamine (TMA);

8 (5) (Blank);

9 (6) Diethyltryptamine (DET);

10 (7) Dimethyltryptamine (DMT);

11 (7.1) 5-Methoxy-diallyltryptamine;

12 (8) 4-methyl-2,5-dimethoxyamphetamine (DOM, STP);

13 (9) Ibogaine (some trade and other names:

14 7-ethyl-6,6,beta,7,8,9,10,12,13-octahydro-2-methoxy-

15 6,9-methano-5H-pyrido [1',2':1,2] azepino [5,4-b]

16 indole; Tabernanthe iboga);

17 (10) Lysergic acid diethylamide;

18 (10.1) Salvinorin A;

19 (10.5) Salvia divinorum (meaning all parts of the  
20 plant presently classified botanically as Salvia  
21 divinorum, whether growing or not, the seeds thereof, any  
22 extract from any part of that plant, and every compound,  
23 manufacture, salts, isomers, and salts of isomers whenever  
24 the existence of such salts, isomers, and salts of isomers  
25 is possible within the specific chemical designation,  
26 derivative, mixture, or preparation of that plant, its



1 seeds or extracts);

2 (11) 3,4,5-trimethoxyphenethylamine (Mescaline);

3 (12) Peyote (meaning all parts of the plant presently  
4 classified botanically as *Lophophora williamsii* Lemaire,  
5 whether growing or not, the seeds thereof, any extract  
6 from any part of that plant, and every compound,  
7 manufacture, salts, derivative, mixture, or preparation of  
8 that plant, its seeds or extracts);

9 (13) N-ethyl-3-piperidyl benzilate (JB 318);

10 (14) N-methyl-3-piperidyl benzilate;

11 (14.1) N-hydroxy-3,4-methylenedioxyamphetamine  
12 (also known as N-hydroxy-alpha-methyl-  
13 3,4(methylenedioxy)phenethylamine and N-hydroxy MDA);

14 (15) Parahexyl; some trade or other names:  
15 3-hexyl-1-hydroxy-7,8,9,10-tetrahydro-6,6,9-trimethyl-6H-  
16 dibenzo (b,d) pyran; Synhexyl;

17 (16) Psilocybin;

18 (17) Psilocyn;

19 (18) Alpha-methyltryptamine (AMT);

20 (19) 2,5-dimethoxyamphetamine  
21 (2,5-dimethoxy-alpha-methylphenethylamine; 2,5-DMA);

22 (20) 4-bromo-2,5-dimethoxyamphetamine  
23 (4-bromo-2,5-dimethoxy-alpha-methylphenethylamine;  
24 4-bromo-2,5-DMA);

25 (20.1) 4-Bromo-2,5 dimethoxyphenethylamine.

26 Some trade or other names: 2-(4-bromo-

1 2,5-dimethoxyphenyl)-1-aminoethane;  
2 alpha-desmethyl DOB, 2CB, Nexus;  
3 (21) 4-methoxyamphetamine  
4 (4-methoxy-alpha-methylphenethylamine;  
5 paramethoxyamphetamine; PMA);  
6 (22) (Blank);  
7 (23) Ethylamine analog of phencyclidine.  
8 Some trade or other names:  
9 N-ethyl-1-phenylcyclohexylamine,  
10 (1-phenylcyclohexyl) ethylamine,  
11 N-(1-phenylcyclohexyl) ethylamine, cyclohexamine, PCE;  
12 (24) Pyrrolidine analog of phencyclidine. Some trade  
13 or other names: 1-(1-phenylcyclohexyl) pyrrolidine, PCPy,  
14 PHP;  
15 (25) 5-methoxy-3,4-methylenedioxy-amphetamine;  
16 (26) 2,5-dimethoxy-4-ethylamphetamine  
17 (another name: DOET);  
18 (27) 1-[1-(2-thienyl)cyclohexyl] pyrrolidine  
19 (another name: TCPy);  
20 (28) (Blank);  
21 (29) Thiophene analog of phencyclidine (some trade  
22 or other names: 1-[1-(2-thienyl)-cyclohexyl]-piperidine;  
23 2-thienyl analog of phencyclidine; TPCP; TCP);  
24 (29.1) Benzothiophene analog of phencyclidine. Some  
25 trade or other names: BTCP or benocyclidine;  
26 (29.2) 3-Methoxyphencyclidine (3-MeO-PCP);

- 1 (30) Bufotenine (some trade or other names:  
2 3-(Beta-Dimethylaminoethyl)-5-hydroxyindole;  
3 3-(2-dimethylaminoethyl)-5-indolol;  
4 5-hydroxy-N,N-dimethyltryptamine;  
5 N,N-dimethylserotonin; mappine);
- 6 (31) (Blank);
- 7 (32) (Blank);
- 8 (33) (Blank);
- 9 (34) (Blank);
- 10 (34.5) (Blank);
- 11 (35) (6aR,10aR)-9-(hydroxymethyl)-6,6-dimethyl-3-  
12 (2-methyloctan-2-yl)-6a,7,  
13 10,10a-tetrahydrobenzo[c]chromen-1-ol  
14 Some trade or other names: HU-210;
- 15 (35.5) (6aS,10aS)-9-(hydroxymethyl)-6,6-  
16 dimethyl-3-(2-methyloctan-2-yl)-6a,7,10,10a-  
17 tetrahydrobenzo[c]chromen-1-ol, its isomers,  
18 salts, and salts of isomers; Some trade or other  
19 names: HU-210, Dexanabinol;
- 20 (36) Dexanabinol, (6aS,10aS)-9-(hydroxymethyl)-  
21 6,6-dimethyl-3-(2-methyloctan-2-yl)-  
22 6a,7,10,10a-tetrahydrobenzo[c]chromen-1-ol  
23 Some trade or other names: HU-211;
- 24 (37) (Blank);
- 25 (38) (Blank);
- 26 (39) (Blank);

1 (40) (Blank);

2 (41) (Blank);

3 (42) Any compound structurally derived from  
4 3-(1-naphthoyl)indole or  
5 1H-indol-3-yl-(1-naphthyl)methane by substitution at the  
6 nitrogen atom of the indole ring by alkyl, haloalkyl,  
7 alkenyl, cycloalkylmethyl, cycloalkylethyl, aryl halide,  
8 alkyl aryl halide, 1-(N-methyl-2-piperidinyl)methyl, or  
9 2-(4-morpholinyl)ethyl whether or not further substituted  
10 in the indole ring to any extent, whether or not  
11 substituted in the naphthyl ring to any extent. Examples  
12 of this structural class include, but are not limited to,  
13 JWH-018, AM-2201, JWH-175, JWH-184, and JWH-185;

14 (43) Any compound structurally derived from  
15 3-(1-naphthoyl)pyrrole by substitution at the nitrogen  
16 atom of the pyrrole ring by alkyl, haloalkyl, alkenyl,  
17 cycloalkylmethyl, cycloalkylethyl, aryl halide, alkyl aryl  
18 halide, 1-(N-methyl-2-piperidinyl)methyl, or  
19 2-(4-morpholinyl)ethyl, whether or not further substituted  
20 in the pyrrole ring to any extent, whether or not  
21 substituted in the naphthyl ring to any extent. Examples  
22 of this structural class include, but are not limited to,  
23 JWH-030, JWH-145, JWH-146, JWH-307, and JWH-368;

24 (44) Any compound structurally derived from  
25 1-(1-naphthylmethyl)indene by substitution at the  
26 3-position of the indene ring by alkyl, haloalkyl,

1        alkenyl, cycloalkylmethyl, cycloalkylethyl, aryl halide,  
2        alkyl aryl halide, 1-(N-methyl-2-piperidinyl)methyl, or  
3        2-(4-morpholinyl)ethyl whether or not further substituted  
4        in the indene ring to any extent, whether or not  
5        substituted in the naphthyl ring to any extent. Examples  
6        of this structural class include, but are not limited to,  
7        JWH-176;

8            (45) Any compound structurally derived from  
9        3-phenylacetylindole by substitution at the nitrogen atom  
10       of the indole ring with alkyl, haloalkyl, alkenyl,  
11       cycloalkylmethyl, cycloalkylethyl, aryl halide, alkyl aryl  
12       halide,        1-(N-methyl-2-piperidinyl)methyl,        or  
13       2-(4-morpholinyl)ethyl, whether or not further substituted  
14       in the indole ring to any extent, whether or not  
15       substituted in the phenyl ring to any extent. Examples of  
16       this structural class include, but are not limited to,  
17       JWH-167, JWH-250, JWH-251, and RCS-8;

18            (46) Any compound structurally derived from  
19        2-(3-hydroxycyclohexyl)phenol by substitution at the  
20        5-position of the phenolic ring by alkyl, haloalkyl,  
21        alkenyl, cycloalkylmethyl, cycloalkylethyl, aryl halide,  
22        alkyl aryl halide, 1-(N-methyl-2-piperidinyl)methyl, or  
23        2-(4-morpholinyl)ethyl, whether or not substituted in the  
24        cyclohexyl ring to any extent. Examples of this structural  
25        class include, but are not limited to, CP 47, 497 and its  
26        C8 homologue (cannabicyclohexanol);

1           (46.1) Any compound structurally derived from  
2           3-(benzoyl) indole with substitution at the nitrogen atom  
3           of the indole ring by an alkyl, haloalkyl, alkenyl,  
4           cycloalkylmethyl, cycloalkylethyl, aryl halide, alkyl aryl  
5           halide,           1-(N-methyl-2-piperidinyl)methyl,           or  
6           2-(4-morpholinyl)ethyl group whether or not further  
7           substituted in the indole ring to any extent and whether  
8           or not substituted in the phenyl ring to any extent.  
9           Examples of this structural class include, but are not  
10          limited to, AM-630, AM-2233, AM-694, Pravadoline (WIN  
11          48,098), and RCS-4;

12           (47) (Blank);

13           (48) (Blank);

14           (49) (Blank);

15           (50) (Blank);

16           (51) (Blank);

17           (52) (Blank);

18           (53)    2,5-Dimethoxy-4-(n)-propylthio-phenethylamine.

19          Some trade or other names: 2C-T-7;

20           (53.1)    4-ethyl-2,5-dimethoxyphenethylamine.    Some  
21          trade or other names: 2C-E;

22           (53.2)    2,5-dimethoxy-4-methylphenethylamine.    Some  
23          trade or other names: 2C-D;

24           (53.3)    4-chloro-2,5-dimethoxyphenethylamine.    Some  
25          trade or other names: 2C-C;

26           (53.4) 4-iodo-2,5-dimethoxyphenethylamine. Some trade

1 or other names: 2C-I;

2 (53.5) 4-ethylthio-2,5-dimethoxyphenethylamine. Some  
3 trade or other names: 2C-T-2;

4 (53.6) 2,5-dimethoxy-4-isopropylthio-phenethylamine.  
5 Some trade or other names: 2C-T-4;

6 (53.7) 2,5-dimethoxyphenethylamine. Some trade or  
7 other names: 2C-H;

8 (53.8) 2,5-dimethoxy-4-nitrophenethylamine. Some  
9 trade or other names: 2C-N;

10 (53.9) 2,5-dimethoxy-4-(n)-propylphenethylamine. Some  
11 trade or other names: 2C-P;

12 (53.10) 2,5-dimethoxy-3,4-dimethylphenethylamine.  
13 Some trade or other names: 2C-G;

14 (53.11) The N-(2-methoxybenzyl) derivative of any 2C  
15 phenethylamine referred to in subparagraphs (20.1), (53),  
16 (53.1), (53.2), (53.3), (53.4), (53.5), (53.6), (53.7),  
17 (53.8), (53.9), and (53.10) including, but not limited to,  
18 25I-NBOMe and 25C-NBOMe;

19 (54) 5-Methoxy-N,N-diisopropyltryptamine;

20 (55) (Blank);

21 (56) (Blank);

22 (57) (Blank);

23 (58) (Blank);

24 (59) 3-cyclopropoylindole with substitution at the  
25 nitrogen atom of the indole ring by alkyl, haloalkyl,  
26 alkenyl, cycloalkylmethyl, cycloalkylethyl, aryl halide,

1 alkyl aryl halide, 1-(N-methyl-2-piperidinyl)methyl, or  
2 2-(4-morpholinyl)ethyl, whether or not further substituted  
3 on the indole ring to any extent, whether or not  
4 substituted on the cyclopropyl ring to any extent:  
5 including, but not limited to, XLR11, UR144, FUB-144;

6 (60) 3-adamantoylindole with substitution at the  
7 nitrogen atom of the indole ring by alkyl, haloalkyl,  
8 alkenyl, cycloalkylmethyl, cycloalkylethyl, aryl halide,  
9 alkyl aryl halide, 1-(N-methyl-2-piperidinyl)methyl, or  
10 2-(4-morpholinyl)ethyl, whether or not further substituted  
11 on the indole ring to any extent, whether or not  
12 substituted on the adamantyl ring to any extent:  
13 including, but not limited to, AB-001;

14 (61) N-(adamantyl)-indole-3-carboxamide with  
15 substitution at the nitrogen atom of the indole ring by  
16 alkyl, haloalkyl, alkenyl, cycloalkylmethyl,  
17 cycloalkylethyl, aryl halide, alkyl aryl halide,  
18 1-(N-methyl-2-piperidinyl)methyl, or  
19 2-(4-morpholinyl)ethyl, whether or not further substituted  
20 on the indole ring to any extent, whether or not  
21 substituted on the adamantyl ring to any extent:  
22 including, but not limited to, APICA/2NE-1, STS-135;

23 (62) N-(adamantyl)-indazole-3-carboxamide with  
24 substitution at a nitrogen atom of the indazole ring by  
25 alkyl, haloalkyl, alkenyl, cycloalkylmethyl,  
26 cycloalkylethyl, aryl halide, alkyl aryl halide,



1 1-(N-methyl-2-piperidinyl)methyl, or  
2 2-(4-morpholinyl)ethyl, whether or not further substituted  
3 on the indazole ring to any extent, whether or not  
4 substituted on the adamantyl ring to any extent:  
5 including, but not limited to, AKB48, 5F-AKB48;

6 (63) 1H-indole-3-carboxylic acid 8-quinolinyl ester  
7 with substitution at the nitrogen atom of the indole ring  
8 by alkyl, haloalkyl, alkenyl, cycloalkylmethyl,  
9 cycloalkylethyl, aryl halide, alkyl aryl halide,  
10 1-(N-methyl-2-piperidinyl)methyl, or  
11 2-(4-morpholinyl)ethyl, whether or not further substituted  
12 on the indole ring to any extent, whether or not  
13 substituted on the quinoline ring to any extent:  
14 including, but not limited to, PB22, 5F-PB22, FUB-PB-22;

15 (64) 3-(1-naphthoyl)indazole with substitution at the  
16 nitrogen atom of the indazole ring by alkyl, haloalkyl,  
17 alkenyl, cycloalkylmethyl, cycloalkylethyl, aryl halide,  
18 alkyl aryl halide, 1-(N-methyl-2-piperidinyl)methyl, or  
19 2-(4-morpholinyl)ethyl, whether or not further substituted  
20 on the indazole ring to any extent, whether or not  
21 substituted on the naphthyl ring to any extent: including,  
22 but not limited to, THJ-018, THJ-2201;

23 (65) 2-(1-naphthoyl)benzimidazole with substitution  
24 at the nitrogen atom of the benzimidazole ring by alkyl,  
25 haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl,  
26 aryl halide, alkyl aryl halide,

1 1-(N-methyl-2-piperidinyl)methyl, or  
2 2-(4-morpholinyl)ethyl, whether or not further substituted  
3 on the benzimidazole ring to any extent, whether or not  
4 substituted on the naphthyl ring to any extent: including,  
5 but not limited to, FUBIMINA;

6 (66)

7 N-(1-amino-3-methyl-1-oxobutan-2-yl)-1H-indazole-  
8 3-carboxamide with substitution on the nitrogen atom of  
9 the indazole ring by alkyl, haloalkyl, alkenyl,  
10 cycloalkylmethyl, cycloalkylethyl, aryl halide, alkyl aryl  
11 halide, 1-(N-methyl-2-piperidinyl)methyl, or  
12 2-(4-morpholinyl)ethyl, whether or not further substituted  
13 on the indazole ring to any extent: including, but not  
14 limited to, AB-PINACA, AB-FUBINACA, AB-CHMINACA;

15 (67) N-(1-amino-3,3-dimethyl-1-oxobutan-2-yl)-1H-  
16 indazole-3-carboxamide with substitution on the nitrogen  
17 atom of the indazole ring by alkyl, haloalkyl, alkenyl,  
18 cycloalkylmethyl, cycloalkylethyl, aryl halide, alkyl aryl  
19 halide, 1-(N-methyl-2-piperidinyl)methyl, or  
20 2-(4-morpholinyl)ethyl, whether or not further substituted  
21 on the indazole ring to any extent: including, but not  
22 limited to, ADB-PINACA, ADB-FUBINACA;

23 (68) N-(1-amino-3,3-dimethyl-1-oxobutan-2-yl)-1H-  
24 indole-3-carboxamide with substitution on the nitrogen  
25 atom of the indole ring by alkyl, haloalkyl, alkenyl,  
26 cycloalkylmethyl, cycloalkylethyl, aryl halide, alkyl aryl

1 halide, 1-(N-methyl-2-piperidinyl)methyl, or  
2 2-(4-morpholinyl)ethyl, whether or not further substituted  
3 on the indole ring to any extent: including, but not  
4 limited to, ADBICA, 5F-ADBICA;

5 (69) N-(1-amino-3-methyl-1-oxobutan-2-yl)-1H-indole-  
6 3-carboxamide with substitution on the nitrogen atom of  
7 the indole ring by alkyl, haloalkyl, alkenyl,  
8 cycloalkylmethyl, cycloalkylethyl, aryl halide, alkyl aryl  
9 halide, 1-(N-methyl-2-piperidinyl)methyl, or  
10 2-(4-morpholinyl)ethyl, whether or not further substituted  
11 on the indole ring to any extent: including, but not  
12 limited to, ABICA, 5F-ABICA;

13 (70) Methyl 2-(1H-indazole-3-carboxamido)-3-  
14 methylbutanoate with substitution on the nitrogen atom of  
15 the indazole ring by alkyl, haloalkyl, alkenyl,  
16 cycloalkylmethyl, cycloalkylethyl, aryl halide, alkyl aryl  
17 halide, 1-(N-methyl-2-piperidinyl)methyl, or  
18 2-(4-morpholinyl)ethyl, whether or not further substituted  
19 on the indazole ring to any extent: including, but not  
20 limited to, AMB, 5F-AMB;

21 (71) Methyl 2-(1H-indazole-3-carboxamido)-3,3-  
22 dimethylbutanoate with substitution on the nitrogen atom  
23 of the indazole ring by alkyl, haloalkyl, alkenyl,  
24 cycloalkylmethyl, cycloalkylethyl, aryl halide, alkyl aryl  
25 halide, 1-(N-methyl-2-piperidinyl)methyl, or  
26 2-(4-morpholinyl)ethyl, whether or not further substituted

1 on the indazole ring to any extent: including, but not  
2 limited to, 5-fluoro-MDMB-PINACA, MDMB-FUBINACA;

3 (72) Methyl 2-(1H-indole-3-carboxamido)-3-  
4 methylbutanoate with substitution on the nitrogen atom of  
5 the indole ring by alkyl, haloalkyl, alkenyl,  
6 cycloalkylmethyl, cycloalkylethyl, aryl halide, alkyl aryl  
7 halide, 1-(N-methyl-2-piperidinyl)methyl, or  
8 2-(4-morpholinyl)ethyl, whether or not further substituted  
9 on the indazole ring to any extent: including, but not  
10 limited to, MMB018, MMB2201, and AMB-CHMICA;

11 (73) Methyl 2-(1H-indole-3-carboxamido)-3,3-  
12 dimethylbutanoate with substitution on the nitrogen atom  
13 of the indole ring by alkyl, haloalkyl, alkenyl,  
14 cycloalkylmethyl, cycloalkylethyl, aryl halide, alkyl aryl  
15 halide, 1-(N-methyl-2-piperidinyl)methyl, or  
16 2-(4-morpholinyl)ethyl, whether or not further substituted  
17 on the indazole ring to any extent: including, but not  
18 limited to, MDMB-CHMICA;

19 (74) N-(1-Amino-1-oxo-3-phenylpropan-2-yl)-1H-  
20 indazole-3-carboxamide with substitution on the nitrogen  
21 atom of the indazole ring by alkyl, haloalkyl, alkenyl,  
22 cycloalkylmethyl, cycloalkylethyl, aryl halide, alkyl aryl  
23 halide, 1-(N-methyl-2-piperidinyl)methyl, or  
24 2-(4-morpholinyl)ethyl, whether or not further substituted  
25 on the indazole ring to any extent: including, but not  
26 limited to, APP-CHMINACA, 5-fluoro-APP-PINACA;

1 (75) N-(1-Amino-1-oxo-3-phenylpropan-2-yl)-1H-indole-  
2 3-carboxamide with substitution on the nitrogen atom of  
3 the indole ring by alkyl, haloalkyl, alkenyl,  
4 cycloalkylmethyl, cycloalkylethyl, aryl halide, alkyl aryl  
5 halide, 1-(N-methyl-2-piperidinyl)methyl, or  
6 2-(4-morpholinyl)ethyl, whether or not further substituted  
7 on the indazole ring to any extent: including, but not  
8 limited to, APP-PICA and 5-fluoro-APP-PICA;

9 (76) 4-Acetoxy-N,N-dimethyltryptamine: trade name  
10 4-AcO-DMT;

11 (77) 5-Methoxy-N-methyl-N-isopropyltryptamine: trade  
12 name 5-MeO-MIPT;

13 (78) 4-hydroxy Diethyltryptamine (4-HO-DET);

14 (79) 4-hydroxy-N-methyl-N-ethyltryptamine (4-HO-MET);

15 (80) 4-hydroxy-N,N-diisopropyltryptamine (4-HO-DiPT);

16 (81) 4-hydroxy-N-methyl-N-isopropyltryptamine  
17 (4-HO-MiPT);

18 (82) Fluorophenylpiperazine;

19 (83) Methoxetamine;

20 (84) 1-(Ethylamino)-2-phenylpropan-2-one (iso-  
21 ethcathinone).

22 (e) Unless specifically excepted or unless listed in  
23 another schedule, any material, compound, mixture, or  
24 preparation which contains any quantity of the following  
25 substances having a depressant effect on the central nervous  
26 system, including its salts, isomers, and salts of isomers

1 whenever the existence of such salts, isomers, and salts of  
2 isomers is possible within the specific chemical designation:

- 3 (1) mecloqualone;
- 4 (2) methaqualone; and
- 5 (3) gamma hydroxybutyric acid.

6 (f) Unless specifically excepted or unless listed in  
7 another schedule, any material, compound, mixture, or  
8 preparation which contains any quantity of the following  
9 substances having a stimulant effect on the central nervous  
10 system, including its salts, isomers, and salts of isomers:

- 11 (1) Fenethylamine;
- 12 (2) N-ethylamphetamine;
- 13 (3) Aminorex (some other names:

14 2-amino-5-phenyl-2-oxazoline; aminoxaphen;  
15 4-5-dihydro-5-phenyl-2-oxazolamine) and its  
16 salts, optical isomers, and salts of optical isomers;

- 17 (4) Methcathinone (some other names:

18 2-methylamino-1-phenylpropan-1-one;  
19 Ephedrone; 2-(methylamino)-propionophenone;  
20 alpha-(methylamino)propionophenone; N-methylcathinone;  
21 methcathinone; Monomethylpropion; UR 1431) and its  
22 salts, optical isomers, and salts of optical isomers;

- 23 (5) Cathinone (some trade or other names:

24 2-aminopropionophenone; alpha-aminopropionophenone;  
25 2-amino-1-phenyl-propanone; norephedrone);

- 26 (6) N,N-dimethylamphetamine (also known as:

1 N,N-alpha-trimethyl-benzeneethanamine;

2 N,N-alpha-trimethylphenethylamine);

3 (7) (+ or -) cis-4-methylaminorex ((+ or -) cis-  
4 4,5-dihydro-4-methyl-4-5-phenyl-2-oxazolamine);

5 (8) 3,4-Methylenedioxypropylvalerone (MDPV);

6 (9) Halogenated amphetamines and

7 methamphetamines - any compound derived from either

8 amphetamine or methamphetamine through the substitution

9 of a halogen on the phenyl ring, including, but not

10 limited to, 2-fluoroamphetamine, 3-

11 fluoroamphetamine and 4-fluoroamphetamine;

12 (10) Aminopropylbenzofuran (APB):

13 including 4-(2-Aminopropyl) benzofuran, 5-

14 (2-Aminopropyl)benzofuran, 6-(2-Aminopropyl)

15 benzofuran, and 7-(2-Aminopropyl) benzofuran;

16 (11) Aminopropyl-dihydrobenzofuran (APDB):

17 including 4-(2-Aminopropyl)-2,3- dihydrobenzofuran,

18 5-(2-Aminopropyl)-2, 3-dihydrobenzofuran,

19 6-(2-Aminopropyl)-2,3-dihydrobenzofuran,

20 and 7-(2-Aminopropyl)-2,3-dihydrobenzofuran;

21 (12) Methylaminopropylbenzofuran

22 (MAPB): including 4-(2-methylaminopropyl)

23 benzofuran, 5-(2-methylaminopropyl)benzofuran,

24 6-(2-methylaminopropyl)benzofuran

25 and 7-(2-methylaminopropyl)benzofuran.

26 (g) Temporary listing of substances subject to emergency

1 scheduling. Any material, compound, mixture, or preparation  
2 that contains any quantity of the following substances:

3 (1) N-[1-benzyl-4-piperidyl]-N-phenylpropanamide  
4 (benzylfentanyl), its optical isomers, isomers, salts, and  
5 salts of isomers;

6 (2) N-[1(2-thienyl) methyl-4-piperidyl]-N-  
7 phenylpropanamide (thenylfentanyl), its optical isomers,  
8 salts, and salts of isomers.

9 (h) Synthetic cathinones. Unless specifically excepted,  
10 any chemical compound which is not approved by the United  
11 States Food and Drug Administration or, if approved, is not  
12 dispensed or possessed in accordance with State or federal  
13 law, not including bupropion, structurally derived from  
14 2-aminopropan-1-one by substitution at the 1-position with  
15 either phenyl, naphthyl, or thiophene ring systems, whether or  
16 not the compound is further modified in one or more of the  
17 following ways:

18 (1) by substitution in the ring system to any extent  
19 with alkyl, alkylendioxy, alkoxy, haloalkyl, hydroxyl, or  
20 halide substituents, whether or not further substituted in  
21 the ring system by one or more other univalent  
22 substituents. Examples of this class include, but are not  
23 limited to, 3,4-Methylenedioxycathinone (bk-MDA);

24 (2) by substitution at the 3-position with an acyclic  
25 alkyl substituent. Examples of this class include, but are  
26 not limited to, 2-methylamino-1-phenylbutan-1-one



1 (buphedrone); or

2 (3) by substitution at the 2-amino nitrogen atom with  
3 alkyl, dialkyl, benzyl, or methoxybenzyl groups, or by  
4 inclusion of the 2-amino nitrogen atom in a cyclic  
5 structure. Examples of this class include, but are not  
6 limited to, Dimethylcathinone, Ethcathinone, and  
7  $\alpha$ -Pyrrolidinopropiophenone ( $\alpha$ -PPP); or

8 Any other synthetic cathinone which is not approved by the  
9 United States Food and Drug Administration or, if approved, is  
10 not dispensed or possessed in accordance with State or federal  
11 law.

12 (i) Synthetic cannabinoids or piperazines. Any synthetic  
13 cannabinoid or piperazine which is not approved by the United  
14 States Food and Drug Administration or, if approved, which is  
15 not dispensed or possessed in accordance with State and  
16 federal law.

17 (Source: P.A. 99-371, eff. 1-1-16; 100-201, eff. 8-18-17;  
18 100-368, eff. 1-1-18; 100-789, eff. 1-1-19; 100-863, eff.  
19 8-14-18.)

20 (Text of Section after amendment by P.A. 103-245)

21 Sec. 204. (a) The controlled substances listed in this  
22 Section are included in Schedule I.

23 (b) Unless specifically excepted or unless listed in  
24 another schedule, any of the following opiates, including  
25 their isomers, esters, ethers, salts, and salts of isomers,

1 esters, and ethers, whenever the existence of such isomers,  
2 esters, ethers and salts is possible within the specific  
3 chemical designation:

4 (1) Acetylmethadol;

5 (1.1) Acetyl-alpha-methylfentanyl

6 (N-[1-(1-methyl-2-phenethyl)-

7 4-piperidinyl]-N-phenylacetamide);

8 (2) Allylprodine;

9 (3) Alphacetylmethadol, except

10 levo-alphacetylmethadol (also known as levo-alpha-  
11 acetylmethadol, levomethadyl acetate, or LAAM);

12 (4) Alphameprodine;

13 (5) Alphamethadol;

14 (6) Alpha-methylfentanyl

15 (N-(1-alpha-methyl-beta-phenyl) ethyl-4-piperidyl)  
16 propionanilide; 1-(1-methyl-2-phenylethyl)-4-(N-  
17 propanilido) piperidine;

18 (6.1) Alpha-methylthiofentanyl

19 (N-[1-methyl-2-(2-thienyl)ethyl-

20 4-piperidinyl]-N-phenylpropanamide);

21 (7) 1-methyl-4-phenyl-4-propionoxypiperidine (MPPP);

22 (7.1) PEPAP

23 (1-(2-phenethyl)-4-phenyl-4-acetoxypiperidine);

24 (8) Benzethidine;

25 (9) Betacetylmethadol;

26 (9.1) Beta-hydroxyfentanyl

1 (N-[1-(2-hydroxy-2-phenethyl)-  
2 4-piperidinyll-N-phenylpropanamide);  
3 (10) Betameprodine;  
4 (11) Betamethadol;  
5 (12) Betaprodine;  
6 (13) Clonitazene;  
7 (14) Dextromoramide;  
8 (15) Diampromide;  
9 (16) Diethylthiambutene;  
10 (17) Difenoquin;  
11 (18) Dimenoxadol;  
12 (19) Dimepheptanol;  
13 (20) Dimethylthiambutene;  
14 (21) Dioxaphetylbutyrate;  
15 (22) Dipipanone;  
16 (23) Ethylmethylthiambutene;  
17 (24) Etonitazene;  
18 (25) Etoxadine;  
19 (26) Furethidine;  
20 (27) Hydroxypethidine;  
21 (28) Ketobemidone;  
22 (29) Levomoramide;  
23 (30) Levophenacetylmorphan;  
24 (31) 3-Methylfentanyl  
25 (N-[3-methyl-1-(2-phenylethyl)-  
26 4-piperidyl]-N-phenylpropanamide);

- 1 (31.1) 3-Methylthiofentanyl  
2 (N-[ (3-methyl-1-(2-thienyl)ethyl-  
3 4-piperidinyl]-N-phenylpropanamide);  
4 (32) Morpheridine;  
5 (33) Noracymethadol;  
6 (34) Norlevorphanol;  
7 (35) Normethadone;  
8 (36) Norpipanone;  
9 (36.1) Para-fluorofentanyl  
10 (N-(4-fluorophenyl)-N-[1-(2-phenethyl)-  
11 4-piperidinyl]propanamide);  
12 (37) Phenadoxone;  
13 (38) Phenampromide;  
14 (39) Phenomorphan;  
15 (40) Phenoperidine;  
16 (41) Piritramide;  
17 (42) Proheptazine;  
18 (43) Properidine;  
19 (44) Propiram;  
20 (45) Racemoramide;  
21 (45.1) Thiofentanyl  
22 (N-phenyl-N-[1-(2-thienyl)ethyl-  
23 4-piperidinyl]-propanamide);  
24 (46) Tilidine;  
25 (47) Trimeperidine;  
26 (48) Beta-hydroxy-3-methylfentanyl (other name:

1 N-[1-(2-hydroxy-2-phenethyl)-3-methyl-4-piperidinyl]-  
2 N-phenylpropanamide);

3 (49) Furanyl fentanyl (FU-F);

4 (50) Butyryl fentanyl;

5 (51) Valeryl fentanyl;

6 (52) Acetyl fentanyl;

7 (53) Beta-hydroxy-thiofentanyl;

8 (54) 3,4-dichloro-N-[2-

9 (dimethylamino)cyclohexyl]-N-

10 methylbenzamide (U-47700);

11 (55) 4-chloro-N-[1-[2-

12 (4-nitrophenyl)ethyl]-2-piperidinylidene]-

13 benzenesulfonamide (W-18);

14 (56) 4-chloro-N-[1-(2-phenylethyl)

15 -2-piperidinylidene]-benzenesulfonamide (W-15);

16 (57) acrylfentanyl (acryloylfentanyl).

17 (c) Unless specifically excepted or unless listed in  
18 another schedule, any of the following opium derivatives, its  
19 salts, isomers and salts of isomers, whenever the existence of  
20 such salts, isomers and salts of isomers is possible within  
21 the specific chemical designation:

22 (1) Acetorphine;

23 (2) Acetyldihydrocodeine;

24 (3) Benzylmorphine;

25 (4) Codeine methylbromide;

26 (5) Codeine-N-Oxide;

- 1 (6) Cyprenorphine;
- 2 (7) Desomorphine;
- 3 (8) Diacetyldihydromorphine (Dihydroheroin);
- 4 (9) Dihydromorphine;
- 5 (10) Drotebanol;
- 6 (11) Etorphine (except hydrochloride salt);
- 7 (12) Heroin;
- 8 (13) Hydromorphenol;
- 9 (14) Methyldesorphine;
- 10 (15) Methyldihydromorphine;
- 11 (16) Morphine methylbromide;
- 12 (17) Morphine methylsulfonate;
- 13 (18) Morphine-N-Oxide;
- 14 (19) Myrophine;
- 15 (20) Nicocodeine;
- 16 (21) Nicomorphine;
- 17 (22) Normorphine;
- 18 (23) Pholcodine;
- 19 (24) Thebacon.

20 (d) Unless specifically excepted or unless listed in  
21 another schedule, any material, compound, mixture, or  
22 preparation which contains any quantity of the following  
23 hallucinogenic substances, or which contains any of its salts,  
24 isomers and salts of isomers, whenever the existence of such  
25 salts, isomers, and salts of isomers is possible within the  
26 specific chemical designation (for the purposes of this

1 paragraph only, the term "isomer" includes the optical,  
2 position and geometric isomers):

3 (1) 3,4-methylenedioxyamphetamine

4 (alpha-methyl,3,4-methylenedioxyphenethylamine,  
5 methylenedioxyamphetamine, MDA);

6 (1.1) Alpha-ethyltryptamine

7 (some trade or other names: etryptamine;  
8 MONASE; alpha-ethyl-1H-indole-3-ethanamine;  
9 3-(2-aminobutyl)indole; a-ET; and AET);

10 (2) 3,4-methylenedioxymethamphetamine (MDMA);

11 (2.1) 3,4-methylenedioxy-N-ethylamphetamine

12 (also known as: N-ethyl-alpha-methyl-  
13 3,4(methylenedioxy) Phenethylamine, N-ethyl MDA, MDE,  
14 and MDEA);

15 (2.2) N-Benzylpiperazine (BZP);

16 (2.2-1) Trifluoromethylphenylpiperazine (TFMPP);

17 (3) 3-methoxy-4,5-methylenedioxyamphetamine, (MMDA);

18 (4) 3,4,5-trimethoxyamphetamine (TMA);

19 (5) (Blank);

20 (6) Diethyltryptamine (DET);

21 (7) Dimethyltryptamine (DMT);

22 (7.1) 5-Methoxy-diallyltryptamine;

23 (8) 4-methyl-2,5-dimethoxyamphetamine (DOM, STP);

24 (9) Ibogaine (some trade and other names:

25 7-ethyl-6,6,beta,7,8,9,10,12,13-octahydro-2-methoxy-  
26 6,9-methano-5H-pyrido [1',2':1,2] azepino [5,4-b]

1 indole; Tabernanthe iboga);

2 (10) Lysergic acid diethylamide;

3 (10.1) Salvinorin A;

4 (10.5) Salvia divinorum (meaning all parts of the  
5 plant presently classified botanically as Salvia  
6 divinorum, whether growing or not, the seeds thereof, any  
7 extract from any part of that plant, and every compound,  
8 manufacture, salts, isomers, and salts of isomers whenever  
9 the existence of such salts, isomers, and salts of isomers  
10 is possible within the specific chemical designation,  
11 derivative, mixture, or preparation of that plant, its  
12 seeds or extracts);

13 (11) 3,4,5-trimethoxyphenethylamine (Mescaline);

14 (12) Peyote (meaning all parts of the plant presently  
15 classified botanically as Lophophora williamsii Lemaire,  
16 whether growing or not, the seeds thereof, any extract  
17 from any part of that plant, and every compound,  
18 manufacture, salts, derivative, mixture, or preparation of  
19 that plant, its seeds or extracts);

20 (13) N-ethyl-3-piperidyl benzilate (JB 318);

21 (14) N-methyl-3-piperidyl benzilate;

22 (14.1) N-hydroxy-3,4-methylenedioxyamphetamine

23 (also known as N-hydroxy-alpha-methyl-

24 3,4(methylenedioxy)phenethylamine and N-hydroxy MDA);

25 (15) Parahexyl; some trade or other names:

26 3-hexyl-1-hydroxy-7,8,9,10-tetrahydro-6,6,9-trimethyl-6H-



1           dibenzo (b,d) pyran; Synhexyl;  
2           (16) Psilocybin;  
3           (17) Psilocyn;  
4           (18) Alpha-methyltryptamine (AMT);  
5           (19) 2,5-dimethoxyamphetamine  
6           (2,5-dimethoxy-alpha-methylphenethylamine; 2,5-DMA);  
7           (20) 4-bromo-2,5-dimethoxyamphetamine  
8           (4-bromo-2,5-dimethoxy-alpha-methylphenethylamine;  
9           4-bromo-2,5-DMA);  
10          (20.1) 4-Bromo-2,5 dimethoxyphenethylamine.  
11          Some trade or other names: 2-(4-bromo-  
12          2,5-dimethoxyphenyl)-1-aminoethane;  
13          alpha-desmethyl DOB, 2CB, Nexus;  
14          (21) 4-methoxyamphetamine  
15          (4-methoxy-alpha-methylphenethylamine;  
16          paramethoxyamphetamine; PMA);  
17          (22) (Blank);  
18          (23) Ethylamine analog of phencyclidine.  
19          Some trade or other names:  
20          N-ethyl-1-phenylcyclohexylamine,  
21          (1-phenylcyclohexyl) ethylamine,  
22          N-(1-phenylcyclohexyl) ethylamine, cyclohexamine, PCE;  
23          (24) Pyrrolidine analog of phencyclidine. Some trade  
24          or other names: 1-(1-phenylcyclohexyl) pyrrolidine, PCPy,  
25          PHP;  
26          (25) 5-methoxy-3,4-methylenedioxy-amphetamine;

- 1 (26) 2,5-dimethoxy-4-ethylamphetamine  
2 (another name: DOET);
- 3 (27) 1-[1-(2-thienyl)cyclohexyl] pyrrolidine  
4 (another name: TCPy);
- 5 (28) (Blank);
- 6 (29) Thiophene analog of phencyclidine (some trade  
7 or other names: 1-[1-(2-thienyl)-cyclohexyl]-piperidine;  
8 2-thienyl analog of phencyclidine; TPCP; TCP);
- 9 (29.1) Benzothiophene analog of phencyclidine. Some  
10 trade or other names: BTCP or benocyclidine;
- 11 (29.2) 3-Methoxyphencyclidine (3-MeO-PCP);
- 12 (30) Bufotenine (some trade or other names:  
13 3-(Beta-Dimethylaminoethyl)-5-hydroxyindole;  
14 3-(2-dimethylaminoethyl)-5-indolol;  
15 5-hydroxy-N,N-dimethyltryptamine;  
16 N,N-dimethylserotonin; mappine);
- 17 (31) (Blank);
- 18 (32) (Blank);
- 19 (33) (Blank);
- 20 (34) (Blank);
- 21 (34.5) (Blank);
- 22 (35) (6aR,10aR)-9-(hydroxymethyl)-6,6-dimethyl-3-  
23 (2-methyloctan-2-yl)-6a,7,  
24 10,10a-tetrahydrobenzo[c]chromen-1-ol  
25 Some trade or other names: HU-210;
- 26 (35.5) (6aS,10aS)-9-(hydroxymethyl)-6,6-

1 dimethyl-3-(2-methyloctan-2-yl)-6a,7,10,10a-  
2 tetrahydrobenzo[c]chromen-1-ol, its isomers,  
3 salts, and salts of isomers; Some trade or other  
4 names: HU-210, Dexanabinol;

5 (36) Dexanabinol, (6aS,10aS)-9-(hydroxymethyl)-  
6 6,6-dimethyl-3-(2-methyloctan-2-yl)-  
7 6a,7,10,10a-tetrahydrobenzo[c]chromen-1-ol  
8 Some trade or other names: HU-211;

9 (37) (Blank);

10 (38) (Blank);

11 (39) (Blank);

12 (40) (Blank);

13 (41) (Blank);

14 (42) Any compound structurally derived from  
15 3-(1-naphthoyl)indole or  
16 1H-indol-3-yl-(1-naphthyl)methane by substitution at the  
17 nitrogen atom of the indole ring by alkyl, haloalkyl,  
18 alkenyl, cycloalkylmethyl, cycloalkylethyl, aryl halide,  
19 alkyl aryl halide, 1-(N-methyl-2-piperidinyl)methyl, or  
20 2-(4-morpholinyl)ethyl whether or not further substituted  
21 in the indole ring to any extent, whether or not  
22 substituted in the naphthyl ring to any extent. Examples  
23 of this structural class include, but are not limited to,  
24 JWH-018, AM-2201, JWH-175, JWH-184, and JWH-185;

25 (43) Any compound structurally derived from  
26 3-(1-naphthoyl)pyrrole by substitution at the nitrogen

1 atom of the pyrrole ring by alkyl, haloalkyl, alkenyl,  
2 cycloalkylmethyl, cycloalkylethyl, aryl halide, alkyl aryl  
3 halide, 1-(N-methyl-2-piperidinyl)methyl, or  
4 2-(4-morpholinyl)ethyl, whether or not further substituted  
5 in the pyrrole ring to any extent, whether or not  
6 substituted in the naphthyl ring to any extent. Examples  
7 of this structural class include, but are not limited to,  
8 JWH-030, JWH-145, JWH-146, JWH-307, and JWH-368;

9 (44) Any compound structurally derived from  
10 1-(1-naphthylmethyl)indene by substitution at the  
11 3-position of the indene ring by alkyl, haloalkyl,  
12 alkenyl, cycloalkylmethyl, cycloalkylethyl, aryl halide,  
13 alkyl aryl halide, 1-(N-methyl-2-piperidinyl)methyl, or  
14 2-(4-morpholinyl)ethyl whether or not further substituted  
15 in the indene ring to any extent, whether or not  
16 substituted in the naphthyl ring to any extent. Examples  
17 of this structural class include, but are not limited to,  
18 JWH-176;

19 (45) Any compound structurally derived from  
20 3-phenylacetylindole by substitution at the nitrogen atom  
21 of the indole ring with alkyl, haloalkyl, alkenyl,  
22 cycloalkylmethyl, cycloalkylethyl, aryl halide, alkyl aryl  
23 halide, 1-(N-methyl-2-piperidinyl)methyl, or  
24 2-(4-morpholinyl)ethyl, whether or not further substituted  
25 in the indole ring to any extent, whether or not  
26 substituted in the phenyl ring to any extent. Examples of

1 this structural class include, but are not limited to,  
2 JWH-167, JWH-250, JWH-251, and RCS-8;

3 (46) Any compound structurally derived from  
4 2-(3-hydroxycyclohexyl)phenol by substitution at the  
5 5-position of the phenolic ring by alkyl, haloalkyl,  
6 alkenyl, cycloalkylmethyl, cycloalkylethyl, aryl halide,  
7 alkyl aryl halide, 1-(N-methyl-2-piperidinyl)methyl, or  
8 2-(4-morpholinyl)ethyl, whether or not substituted in the  
9 cyclohexyl ring to any extent. Examples of this structural  
10 class include, but are not limited to, CP 47, 497 and its  
11 C8 homologue (cannabicyclohexanol);

12 (46.1) Any compound structurally derived from  
13 3-(benzoyl) indole with substitution at the nitrogen atom  
14 of the indole ring by an alkyl, haloalkyl, alkenyl,  
15 cycloalkylmethyl, cycloalkylethyl, aryl halide, alkyl aryl  
16 halide, 1-(N-methyl-2-piperidinyl)methyl, or  
17 2-(4-morpholinyl)ethyl group whether or not further  
18 substituted in the indole ring to any extent and whether  
19 or not substituted in the phenyl ring to any extent.  
20 Examples of this structural class include, but are not  
21 limited to, AM-630, AM-2233, AM-694, Pravadoline (WIN  
22 48,098), and RCS-4;

23 (47) (Blank);

24 (48) (Blank);

25 (49) (Blank);

26 (50) (Blank);

1 (51) (Blank);

2 (52) (Blank);

3 (53) 2,5-Dimethoxy-4-(n)-propylthio-phenethylamine.

4 Some trade or other names: 2C-T-7;

5 (53.1) 4-ethyl-2,5-dimethoxyphenethylamine. Some

6 trade or other names: 2C-E;

7 (53.2) 2,5-dimethoxy-4-methylphenethylamine. Some

8 trade or other names: 2C-D;

9 (53.3) 4-chloro-2,5-dimethoxyphenethylamine. Some

10 trade or other names: 2C-C;

11 (53.4) 4-iodo-2,5-dimethoxyphenethylamine. Some trade

12 or other names: 2C-I;

13 (53.5) 4-ethylthio-2,5-dimethoxyphenethylamine. Some

14 trade or other names: 2C-T-2;

15 (53.6) 2,5-dimethoxy-4-isopropylthio-phenethylamine.

16 Some trade or other names: 2C-T-4;

17 (53.7) 2,5-dimethoxyphenethylamine. Some trade or

18 other names: 2C-H;

19 (53.8) 2,5-dimethoxy-4-nitrophenethylamine. Some

20 trade or other names: 2C-N;

21 (53.9) 2,5-dimethoxy-4-(n)-propylphenethylamine. Some

22 trade or other names: 2C-P;

23 (53.10) 2,5-dimethoxy-3,4-dimethylphenethylamine.

24 Some trade or other names: 2C-G;

25 (53.11) The N-(2-methoxybenzyl) derivative of any 2C

26 phenethylamine referred to in subparagraphs (20.1), (53),

1 (53.1), (53.2), (53.3), (53.4), (53.5), (53.6), (53.7),  
2 (53.8), (53.9), and (53.10) including, but not limited to,  
3 25I-NBOMe and 25C-NBOMe;

4 (54) 5-Methoxy-N,N-diisopropyltryptamine;

5 (55) (Blank);

6 (56) (Blank);

7 (57) (Blank);

8 (58) (Blank);

9 (59) 3-cyclopropoylindole with substitution at the  
10 nitrogen atom of the indole ring by alkyl, haloalkyl,  
11 alkenyl, cycloalkylmethyl, cycloalkylethyl, aryl halide,  
12 alkyl aryl halide, 1-(N-methyl-2-piperidinyl)methyl, or  
13 2-(4-morpholinyl)ethyl, whether or not further substituted  
14 on the indole ring to any extent, whether or not  
15 substituted on the cyclopropyl ring to any extent:  
16 including, but not limited to, XLR11, UR144, FUB-144;

17 (60) 3-adamantoylindole with substitution at the  
18 nitrogen atom of the indole ring by alkyl, haloalkyl,  
19 alkenyl, cycloalkylmethyl, cycloalkylethyl, aryl halide,  
20 alkyl aryl halide, 1-(N-methyl-2-piperidinyl)methyl, or  
21 2-(4-morpholinyl)ethyl, whether or not further substituted  
22 on the indole ring to any extent, whether or not  
23 substituted on the adamantyl ring to any extent:  
24 including, but not limited to, AB-001;

25 (61) N-(adamantyl)-indole-3-carboxamide with  
26 substitution at the nitrogen atom of the indole ring by

1 alkyl, haloalkyl, alkenyl, cycloalkylmethyl,  
2 cycloalkylethyl, aryl halide, alkyl aryl halide,  
3 1-(N-methyl-2-piperidinyl)methyl, or  
4 2-(4-morpholinyl)ethyl, whether or not further substituted  
5 on the indole ring to any extent, whether or not  
6 substituted on the adamantyl ring to any extent:  
7 including, but not limited to, APICA/2NE-1, STS-135;

8 (62) N-(adamantyl)-indazole-3-carboxamide with  
9 substitution at a nitrogen atom of the indazole ring by  
10 alkyl, haloalkyl, alkenyl, cycloalkylmethyl,  
11 cycloalkylethyl, aryl halide, alkyl aryl halide,  
12 1-(N-methyl-2-piperidinyl)methyl, or  
13 2-(4-morpholinyl)ethyl, whether or not further substituted  
14 on the indazole ring to any extent, whether or not  
15 substituted on the adamantyl ring to any extent:  
16 including, but not limited to, AKB48, 5F-AKB48;

17 (63) 1H-indole-3-carboxylic acid 8-quinolinyl ester  
18 with substitution at the nitrogen atom of the indole ring  
19 by alkyl, haloalkyl, alkenyl, cycloalkylmethyl,  
20 cycloalkylethyl, aryl halide, alkyl aryl halide,  
21 1-(N-methyl-2-piperidinyl)methyl, or  
22 2-(4-morpholinyl)ethyl, whether or not further substituted  
23 on the indole ring to any extent, whether or not  
24 substituted on the quinoline ring to any extent:  
25 including, but not limited to, PB22, 5F-PB22, FUB-PB-22;

26 (64) 3-(1-naphthoyl)indazole with substitution at the



1 nitrogen atom of the indazole ring by alkyl, haloalkyl,  
2 alkenyl, cycloalkylmethyl, cycloalkylethyl, aryl halide,  
3 alkyl aryl halide, 1-(N-methyl-2-piperidinyl)methyl, or  
4 2-(4-morpholinyl)ethyl, whether or not further substituted  
5 on the indazole ring to any extent, whether or not  
6 substituted on the naphthyl ring to any extent: including,  
7 but not limited to, THJ-018, THJ-2201;

8 (65) 2-(1-naphthoyl)benzimidazole with substitution  
9 at the nitrogen atom of the benzimidazole ring by alkyl,  
10 haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl,  
11 aryl halide, alkyl aryl halide,  
12 1-(N-methyl-2-piperidinyl)methyl, or  
13 2-(4-morpholinyl)ethyl, whether or not further substituted  
14 on the benzimidazole ring to any extent, whether or not  
15 substituted on the naphthyl ring to any extent: including,  
16 but not limited to, FUBIMINA;

17 (66)  
18 N-(1-amino-3-methyl-1-oxobutan-2-yl)-1H-indazole-  
19 3-carboxamide with substitution on the nitrogen atom of  
20 the indazole ring by alkyl, haloalkyl, alkenyl,  
21 cycloalkylmethyl, cycloalkylethyl, aryl halide, alkyl aryl  
22 halide, 1-(N-methyl-2-piperidinyl)methyl, or  
23 2-(4-morpholinyl)ethyl, whether or not further substituted  
24 on the indazole ring to any extent: including, but not  
25 limited to, AB-PINACA, AB-FUBINACA, AB-CHMINACA;

26 (67) N-(1-amino-3,3-dimethyl-1-oxobutan-2-yl)-1H-

1 indazole-3-carboxamide with substitution on the nitrogen  
2 atom of the indazole ring by alkyl, haloalkyl, alkenyl,  
3 cycloalkylmethyl, cycloalkylethyl, aryl halide, alkyl aryl  
4 halide, 1-(N-methyl-2-piperidinyl)methyl, or  
5 2-(4-morpholinyl)ethyl, whether or not further substituted  
6 on the indazole ring to any extent: including, but not  
7 limited to, ADB-PINACA, ADB-FUBINACA;

8 (68) N-(1-amino-3,3-dimethyl-1-oxobutan-2-yl)-1H-  
9 indole-3-carboxamide with substitution on the nitrogen  
10 atom of the indole ring by alkyl, haloalkyl, alkenyl,  
11 cycloalkylmethyl, cycloalkylethyl, aryl halide, alkyl aryl  
12 halide, 1-(N-methyl-2-piperidinyl)methyl, or  
13 2-(4-morpholinyl)ethyl, whether or not further substituted  
14 on the indole ring to any extent: including, but not  
15 limited to, ADBICA, 5F-ADBICA;

16 (69) N-(1-amino-3-methyl-1-oxobutan-2-yl)-1H-indole-  
17 3-carboxamide with substitution on the nitrogen atom of  
18 the indole ring by alkyl, haloalkyl, alkenyl,  
19 cycloalkylmethyl, cycloalkylethyl, aryl halide, alkyl aryl  
20 halide, 1-(N-methyl-2-piperidinyl)methyl, or  
21 2-(4-morpholinyl)ethyl, whether or not further substituted  
22 on the indole ring to any extent: including, but not  
23 limited to, ABICA, 5F-ABICA;

24 (70) Methyl 2-(1H-indazole-3-carboxamido)-3-  
25 methylbutanoate with substitution on the nitrogen atom of  
26 the indazole ring by alkyl, haloalkyl, alkenyl,

1 cycloalkylmethyl, cycloalkylethyl, aryl halide, alkyl aryl  
2 halide, 1-(N-methyl-2-piperidinyl)methyl, or  
3 2-(4-morpholinyl)ethyl, whether or not further substituted  
4 on the indazole ring to any extent: including, but not  
5 limited to, AMB, 5F-AMB;

6 (71) Methyl 2-(1H-indazole-3-carboxamido)-3,3-  
7 dimethylbutanoate with substitution on the nitrogen atom  
8 of the indazole ring by alkyl, haloalkyl, alkenyl,  
9 cycloalkylmethyl, cycloalkylethyl, aryl halide, alkyl aryl  
10 halide, 1-(N-methyl-2-piperidinyl)methyl, or  
11 2-(4-morpholinyl)ethyl, whether or not further substituted  
12 on the indazole ring to any extent: including, but not  
13 limited to, 5-fluoro-MDMB-PINACA, MDMB-FUBINACA;

14 (72) Methyl 2-(1H-indole-3-carboxamido)-3-  
15 methylbutanoate with substitution on the nitrogen atom of  
16 the indole ring by alkyl, haloalkyl, alkenyl,  
17 cycloalkylmethyl, cycloalkylethyl, aryl halide, alkyl aryl  
18 halide, 1-(N-methyl-2-piperidinyl)methyl, or  
19 2-(4-morpholinyl)ethyl, whether or not further substituted  
20 on the indazole ring to any extent: including, but not  
21 limited to, MMB018, MMB2201, and AMB-CHMICA;

22 (73) Methyl 2-(1H-indole-3-carboxamido)-3,3-  
23 dimethylbutanoate with substitution on the nitrogen atom  
24 of the indole ring by alkyl, haloalkyl, alkenyl,  
25 cycloalkylmethyl, cycloalkylethyl, aryl halide, alkyl aryl  
26 halide, 1-(N-methyl-2-piperidinyl)methyl, or

1 2-(4-morpholinyl)ethyl, whether or not further substituted  
2 on the indazole ring to any extent: including, but not  
3 limited to, MDMB-CHMICA;

4 (74) N-(1-Amino-1-oxo-3-phenylpropan-2-yl)-1H-  
5 indazole-3-carboxamide with substitution on the nitrogen  
6 atom of the indazole ring by alkyl, haloalkyl, alkenyl,  
7 cycloalkylmethyl, cycloalkylethyl, aryl halide, alkyl aryl  
8 halide, 1-(N-methyl-2-piperidinyl)methyl, or  
9 2-(4-morpholinyl)ethyl, whether or not further substituted  
10 on the indazole ring to any extent: including, but not  
11 limited to, APP-CHMINACA, 5-fluoro-APP-PINACA;

12 (75) N-(1-Amino-1-oxo-3-phenylpropan-2-yl)-1H-indole-  
13 3-carboxamide with substitution on the nitrogen atom of  
14 the indole ring by alkyl, haloalkyl, alkenyl,  
15 cycloalkylmethyl, cycloalkylethyl, aryl halide, alkyl aryl  
16 halide, 1-(N-methyl-2-piperidinyl)methyl, or  
17 2-(4-morpholinyl)ethyl, whether or not further substituted  
18 on the indazole ring to any extent: including, but not  
19 limited to, APP-PICA and 5-fluoro-APP-PICA;

20 (76) 4-Acetoxy-N,N-dimethyltryptamine: trade name  
21 4-AcO-DMT;

22 (77) 5-Methoxy-N-methyl-N-isopropyltryptamine: trade  
23 name 5-MeO-MIPT;

24 (78) 4-hydroxy Diethyltryptamine (4-HO-DET);

25 (79) 4-hydroxy-N-methyl-N-ethyltryptamine (4-HO-MET);

26 (80) 4-hydroxy-N,N-diisopropyltryptamine (4-HO-DiPT);

- 1           (81)           4-hydroxy-N-methyl-N-isopropyltryptamine  
2           (4-HO-MiPT);  
3           (82) Fluorophenylpiperazine;  
4           (83) Methoxetamine;  
5           (84)       1-(Ethylamino)-2-phenylpropan-2-one       (iso-  
6           ethcathinone).

7           (e) Unless specifically excepted or unless listed in  
8           another schedule, any material, compound, mixture, or  
9           preparation which contains any quantity of the following  
10          substances having a depressant effect on the central nervous  
11          system, including its salts, isomers, and salts of isomers  
12          whenever the existence of such salts, isomers, and salts of  
13          isomers is possible within the specific chemical designation:

- 14           (1) mecloqualone;  
15           (2) methaqualone; and  
16           (3) gamma hydroxybutyric acid.

17          (f) Unless specifically excepted or unless listed in  
18          another schedule, any material, compound, mixture, or  
19          preparation which contains any quantity of the following  
20          substances having a stimulant effect on the central nervous  
21          system, including its salts, isomers, and salts of isomers:

- 22           (1) Fenethylamine;  
23           (2) N-ethylamphetamine;  
24           (3) Aminorex (some other names:  
25           2-amino-5-phenyl-2-oxazoline; aminoxaphen;  
26           4-5-dihydro-5-phenyl-2-oxazolamine) and its

1 salts, optical isomers, and salts of optical isomers;

2 (4) Methcathinone (some other names:

3 2-methylamino-1-phenylpropan-1-one;

4 Ephedrone; 2-(methylamino)-propiofenone;

5 alpha-(methylamino)propiofenone; N-methylcathinone;

6 methycathinone; Monomethylpropion; UR 1431) and its

7 salts, optical isomers, and salts of optical isomers;

8 (5) Cathinone (some trade or other names:

9 2-aminopropiofenone; alpha-aminopropiofenone;

10 2-amino-1-phenyl-propanone; norephedrone);

11 (6) N,N-dimethylamphetamine (also known as:

12 N,N-alpha-trimethyl-benzeneethanamine;

13 N,N-alpha-trimethylphenethylamine);

14 (7) (+ or -) cis-4-methylaminorex ((+ or -) cis-

15 4,5-dihydro-4-methyl-4-5-phenyl-2-oxazolamine);

16 (8) 3,4-Methylenedioxypropylamphetamine (MDPV);

17 (9) Halogenated amphetamines and

18 methamphetamines - any compound derived from either

19 amphetamine or methamphetamine through the substitution

20 of a halogen on the phenyl ring, including, but not

21 limited to, 2-fluoroamphetamine, 3-

22 fluoroamphetamine and 4-fluoroamphetamine;

23 (10) Aminopropylbenzofuran (APB):

24 including 4-(2-Aminopropyl) benzofuran, 5-

25 (2-Aminopropyl)benzofuran, 6-(2-Aminopropyl)

26 benzofuran, and 7-(2-Aminopropyl) benzofuran;

1           (11) Aminopropyl dihydrobenzofuran (APDB):  
2           including 4-(2-Aminopropyl)-2,3- dihydrobenzofuran,  
3           5-(2-Aminopropyl)-2, 3-dihydrobenzofuran,  
4           6-(2-Aminopropyl)-2,3-dihydrobenzofuran,  
5           and 7-(2-Aminopropyl)-2,3-dihydrobenzofuran;

6           (12) Methylaminopropylbenzofuran  
7           (MAPB): including 4-(2-methylaminopropyl)  
8           benzofuran, 5-(2-methylaminopropyl)benzofuran,  
9           6-(2-methylaminopropyl)benzofuran  
10          and 7-(2-methylaminopropyl)benzofuran.

11          (g) Temporary listing of substances subject to emergency  
12          scheduling. Any material, compound, mixture, or preparation  
13          that contains any quantity of the following substances:

14                 (1)           N-[1-benzyl-4-piperidyl]-N-phenylpropanamide  
15                 (benzylfentanyl), its optical isomers, isomers, salts, and  
16                 salts of isomers;

17                 (2)           N-[1(2-thienyl) methyl-4-piperidyl]-N-  
18                 phenylpropanamide (thenylfentanyl), its optical isomers,  
19                 salts, and salts of isomers.

20          (h) Synthetic cathinones. Unless specifically excepted,  
21          any chemical compound which is not approved by the United  
22          States Food and Drug Administration or, if approved, is not  
23          dispensed or possessed in accordance with State or federal  
24          law, not including bupropion, structurally derived from  
25          2-aminopropan-1-one by substitution at the 1-position with  
26          either phenyl, naphthyl, or thiophene ring systems, whether or

1 not the compound is further modified in one or more of the  
2 following ways:

3 (1) by substitution in the ring system to any extent  
4 with alkyl, alkylenedioxy, alkoxy, haloalkyl, hydroxyl, or  
5 halide substituents, whether or not further substituted in  
6 the ring system by one or more other univalent  
7 substituents. Examples of this class include, but are not  
8 limited to, 3,4-Methylenedioxcathinone (bk-MDA);

9 (2) by substitution at the 3-position with an acyclic  
10 alkyl substituent. Examples of this class include, but are  
11 not limited to, 2-methylamino-1-phenylbutan-1-one  
12 (buphedrone); or

13 (3) by substitution at the 2-amino nitrogen atom with  
14 alkyl, dialkyl, benzyl, or methoxybenzyl groups, or by  
15 inclusion of the 2-amino nitrogen atom in a cyclic  
16 structure. Examples of this class include, but are not  
17 limited to, Dimethylcathinone, Ethcathinone, and  
18  $\alpha$ -Pyrrolidinopropiophenone ( $\alpha$ -PPP); or

19 Any other synthetic cathinone which is not approved by the  
20 United States Food and Drug Administration or, if approved, is  
21 not dispensed or possessed in accordance with State or federal  
22 law.

23 (i) Synthetic cannabinoids or piperazines. Any synthetic  
24 cannabinoid or piperazine which is not approved by the United  
25 States Food and Drug Administration or, if approved, which is  
26 not dispensed or possessed in accordance with State and



1 federal law.

2 (j) Unless specifically excepted or listed in another  
3 schedule, any chemical compound which is not approved by the  
4 United States Food and Drug Administration or, if approved, is  
5 not dispensed or possessed in accordance with State or federal  
6 law, and is derived from the following structural classes and  
7 their salts:

8 (1) Benzodiazepine class: A fused 1,4-diazepine and  
9 benzene ring structure with a phenyl connected to the  
10 1,4-diazepine ring, with any substitution(s) or  
11 replacement(s) on the 1,4-diazepine or benzene ring, any  
12 substitution(s) on the phenyl ring, or any combination  
13 thereof. Examples of this class include but are not  
14 limited to: ~~Clonazepam~~, Flualprazolam; or

15 (2) Thienodiazepine class: A fused 1,4-diazepine and  
16 thiophene ring structure with a phenyl connected to the  
17 1,4-diazepine ring, with any substitution(s) or  
18 replacement(s) on the 1,4-diazepine or thiophene ring, any  
19 substitution(s) on the phenyl ring, or any combination  
20 thereof. Examples of this class include but are not  
21 limited to: Etizolam.

22 (Source: P.A. 103-245, eff. 1-1-24.)

23 (720 ILCS 570/206) (from Ch. 56 1/2, par. 1206)

24 Sec. 206. (a) The controlled substances listed in this  
25 Section are included in Schedule II.

1 (b) Unless specifically excepted or unless listed in  
2 another schedule, any of the following substances whether  
3 produced directly or indirectly by extraction from substances  
4 of vegetable origin, or independently by means of chemical  
5 synthesis, or by combination of extraction and chemical  
6 synthesis:

7 (1) Opium and opiates, and any salt, compound,  
8 derivative or preparation of opium or opiate, excluding  
9 apomorphine, dextrorphan, levopropoxyphene, nalbuphine,  
10 nalmefene, naloxone, and naltrexone, and their respective  
11 salts, but including the following:

- 12 (i) Raw Opium;  
13 (ii) Opium extracts;  
14 (iii) Opium fluid extracts;  
15 (iv) Powdered opium;  
16 (v) Granulated opium;  
17 (vi) Tincture of opium;  
18 (vii) Codeine;  
19 (viii) Ethylmorphine;  
20 (ix) Etorphine Hydrochloride;  
21 (x) Hydrocodone;  
22 (xi) Hydromorphone;  
23 (xii) Metopon;  
24 (xiii) Morphine;  
25 (xiii.5) 6-Monoacetylmorphine;  
26 (xiv) Oxycodone;

1 (xv) Oxymorphone;

2 (xv.5) Tapentadol;

3 (xvi) Thebaine;

4 (xvii) Thebaine-derived butorphanol.

5 (xviii) Methorphan, except drug products  
6 containing dextromethorphan that may be dispensed  
7 pursuant to a prescription order of a practitioner and  
8 are sold in compliance with the safety and labeling  
9 standards as set forth by the United States Food and  
10 Drug Administration, or drug products containing  
11 dextromethorphan that are sold in solid, tablet,  
12 liquid, capsule, powder, thin film, or gel form and  
13 which are formulated, packaged, and sold in dosages  
14 and concentrations for use as an over-the-counter drug  
15 product. For the purposes of this Section,  
16 "over-the-counter drug product" means a drug that is  
17 available to consumers without a prescription and sold  
18 in compliance with the safety and labeling standards  
19 as set forth by the United States Food and Drug  
20 Administration.

21 (2) Any salt, compound, isomer, derivative or  
22 preparation thereof which is chemically equivalent or  
23 identical with any of the substances referred to in  
24 subparagraph (1), but not including the isoquinoline  
25 alkaloids of opium;

26 (3) Opium poppy and poppy straw;

1           (4) Coca leaves and any salt, compound, isomer, salt  
2           of an isomer, derivative, or preparation of coca leaves  
3           including cocaine or ecgonine, and any salt, compound,  
4           isomer, derivative, or preparation thereof which is  
5           chemically equivalent or identical with any of these  
6           substances, but not including decocainized coca leaves or  
7           extractions of coca leaves which do not contain cocaine or  
8           ecgonine (for the purpose of this paragraph, the term  
9           "isomer" includes optical, positional and geometric  
10          isomers);

11          (5) Concentrate of poppy straw (the crude extract of  
12          poppy straw in either liquid, solid or powder form which  
13          contains the phenanthrine alkaloids of the opium poppy).

14          (c) Unless specifically excepted or unless listed in  
15          another schedule any of the following opiates, including their  
16          isomers, esters, ethers, salts, and salts of isomers, whenever  
17          the existence of these isomers, esters, ethers and salts is  
18          possible within the specific chemical designation, dextrophan  
19          excepted:

20                (1) Alfentanil;

21                (1.1) Carfentanil;

22                (1.2) Thiafentanil;

23                (2) Alphaprodine;

24                (3) Anileridine;

25                (4) Bezitramide;

26                (5) Bulk Dextropropoxyphene (non-dosage forms);

- 1 (6) Dihydrocodeine;
- 2 (7) Diphenoxylate;
- 3 (8) Fentanyl;
- 4 (9) Sufentanil;
- 5 (9.5) Remifentanil;
- 6 (10) Isomethadone;
- 7 (11) (Blank);
- 8 (12) Levorphanol (Levorphan);
- 9 (13) Metazocine;
- 10 (14) Methadone;
- 11 (15) Methadone-Intermediate,
- 12 4-cyano-2-dimethylamino-4,4-diphenyl-1-butane;
- 13 (16) Moramide-Intermediate,
- 14 2-methyl-3-morpholino-1,1-diphenylpropane-carboxylic
- 15 acid;
- 16 (17) Pethidine (meperidine);
- 17 (18) Pethidine-Intermediate-A,
- 18 4-cyano-1-methyl-4-phenylpiperidine;
- 19 (19) Pethidine-Intermediate-B,
- 20 ethyl-4-phenylpiperidine-4-carboxylate;
- 21 (20) Pethidine-Intermediate-C,
- 22 1-methyl-4-phenylpiperidine-4-carboxylic acid;
- 23 (21) Phenazocine;
- 24 (22) Piminodine;
- 25 (23) Racemethorphan;
- 26 (24) (Blank);

1           (25)   Levo-alpha-acetylmethadol   (some   other   names:  
2           levo-alpha-acetylmethadol, levomethadyl acetate, LAAM).

3           (d)   Unless specifically excepted or unless listed in  
4           another schedule, any material, compound, mixture, or  
5           preparation which contains any quantity of the following  
6           substances having a stimulant effect on the central nervous  
7           system:

8           (1)   Amphetamine, its salts, optical isomers, and salts  
9           of its optical isomers;

10          (2)   Methamphetamine, its salts, isomers, and salts of  
11          its isomers;

12          (3)   Phenmetrazine and its salts;

13          (4)   Methylphenidate;

14          (5)   Lisdexamfetamine.

15          (e)   Unless specifically excepted or unless listed in  
16          another schedule, any material, compound, mixture, or  
17          preparation which contains any quantity of the following  
18          substances having a depressant effect on the central nervous  
19          system, including its salts, isomers, and salts of isomers  
20          whenever the existence of such salts, isomers, and salts of  
21          isomers is possible within the specific chemical designation:

22          (1)   Amobarbital;

23          (2)   Secobarbital;

24          (3)   Pentobarbital;

25          (4)   Pentazocine;

26          (5)   Phencyclidine;

1 (6) Gluthethimide;

2 (7) (Blank).

3 (f) Unless specifically excepted or unless listed in  
4 another schedule, any material, compound, mixture, or  
5 preparation which contains any quantity of the following  
6 substances:

7 (1) Immediate precursor to amphetamine and  
8 methamphetamine:

9 (i) Phenylacetone

10 Some trade or other names: phenyl-2-propanone;

11 P2P; benzyl methyl ketone; methyl benzyl ketone.

12 (2) Immediate precursors to phencyclidine:

13 (i) 1-phenylcyclohexylamine;

14 (ii) 1-piperidinocyclohexanecarbonitrile (PCC).

15 (3) Nabilone.

16 (4) Xylazine: N-(2,6-dimethylphenyl)-5,6-dihydro-  
17 4H-1,3-thiazin-2-amine), including its isomers, esters,  
18 ethers, salts, and salts of isomers, esters, and ethers,  
19 whenever the existence of such isomers, esters, ethers,  
20 and salts is possible within the specific chemical  
21 designation as a Schedule II controlled substance.

22 (g) Clonazepam.

23 (Source: P.A. 100-368, eff. 1-1-18.)

24 Section 95. No acceleration or delay. Where this Act makes  
25 changes in a statute that is represented in this Act by text

1 that is not yet or no longer in effect (for example, a Section  
2 represented by multiple versions), the use of that text does  
3 not accelerate or delay the taking effect of (i) the changes  
4 made by this Act or (ii) provisions derived from any other  
5 Public Act.